New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment